… of metastatic and recurrent thyroid cancer. This chapter summarizes the rationale for
using systemic therapy and the approved drugs in recurrent or metastatic thyroid carcinoma. …

… and systemic therapies on patients’ outcomes. With the introduction of systemic therapy into
the … to determine the proportion of patients who would clinically warrant therapy with a TKI. …

… on systemic therapy for advanced thyroid cancer between 2013 and 2021. At the top of each
bar, N refers to the total number of patients newly initiated on systemic therapy for that year. …

… , novel, systemic therapeutic option for metastatic MTC. Lastly, anaplastic thyroid cancer (ATC) …
Considering the modality of chemotherapy and the expanding field of targeted therapies, …

… For metastatic disease, surgical resection or stereotactic body irradiation is favored over
systemic therapy (eg, lenvatinib, dabrafenib). Antiangiogenic multikinase inhibitors (eg, …

… thyroid cancer (www.cancerstaging.org) [5]. The application of newer targeted systemic
therapies … the optimal timing for initiation of systemic therapy are being actively investigated. This …

… for individuals diagnosed with low‐risk well‐differentiated thyroid cancer; better … of thyroid
cancer has improved thyroid cancer diagnosis and has enabled individualized therapeutic …

… regional control, and systemic therapy) is used. Unresectable Stage IVB patients may also
respond to aggressive multimodal therapy. Stage IVC patients rarely respond to traditional …

… -termed anaplastic thyroid cancer (ATC). ATCs are resistant to standard therapies and are
… current and recently emerged first-line systemic therapy (Dabrafenib and Trametinib) along …

… thyroid cancer (MTC) recently have been FDA-approved for metastatic disease. Nevertheless,
treatment of thyroid cancer resistant to current systemic therapies … , and novel therapies …